文献速递临床试验与 GCP真实世界研究与卫生经济

比较铥激光经尿道前列腺汽化电切术(ThuVARP)与经尿道前列腺电切术(TURP)在英国国家医疗服务体系(NHS)中临床与成本效果的随机对照试验——UNBLOCS试验:随机对照试验研究方案

A randomised controlled trial to determine the clinical and cost effectiveness of thulium laser transurethral vaporesection of the prostate (ThuVARP) versus transurethral resection of the prostate (TURP) in the National Health Service (NHS) - the UNBLOCS trial: a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2017-04-17

UNBLOCS试验为多中心、实用性、随机、对照、平行组研究,计划纳入410例适合前列腺手术的良性前列腺梗阻(BPO)男性,在四所大学教学医院和三所地区综合医院随机接受ThuVARP或标准TURP。主要目的是判断术后12个月时ThuVARP在患者报告的IPSS和最大尿流率(Qmax)上是否与TURP等效。背景指出TURP已标准应用40年、每年约25000例,现有少量研究数据提示ThuVARP可能减少出血、缩短住院和导尿时间、更早恢复正常活动。

要点

  • UNBLOCS为多中心实用性随机对照平行组试验,比较ThuVARP与标准TURP在BPO男性中的效果。
  • 计划随机410例适合前列腺手术者,分布于四所大学教学医院和三所地区综合医院。
  • 主要终点为术后12个月患者报告的IPSS和最大尿流率(Qmax),判断ThuVARP是否与TURP等效。

核心结论

  • 该研究方案旨在为NHS环境下ThuVARP与TURP的比较提供高质量证据,涵盖患者报告、临床和成本效果结局,以支撑和 inform 未来NICE指南。

研究设计与样本

  • 多中心、实用性、随机、对照、平行组试验,比较ThuVARP与标准TURP在良性前列腺梗阻(BPO)男性中的效果。
  • 计划随机410例适合前列腺手术的男性,在四所大学教学医院和三所地区综合医院入组。
  • 主要目的是判断术后12个月时ThuVARP在患者报告的IPSS和最大尿流率(Qmax)上是否与TURP等效。

主要发现

  • 背景指出TURP作为BPO标准手术已40年,每年约完成25000例,总体成功但有明确风险。
  • 现有少量研究数据提示ThuVARP可能较TURP减少出血、缩短住院时间、更早恢复正常活动和缩短导尿时间。
  • 一项随机对照试验的初步证据显示ThuVARP临床效果与TURP等效,并具有其他潜在优势。

关键数值与推荐

  • 主要等效性判断基于术后12个月的患者报告国际前列腺症状评分(IPSS)和最大尿流率(Qmax)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transurethral resection of the prostate (TURP) has been the standard operation for benign prostatic obstruction (BPO) for 40 years, with approximately 25,000 procedures performed annually, and has remained largely unchanged. It is generally a successful operation, but has well-documented risks for the patient. Thulium laser transurethral vaporesection of the prostate (ThuVARP) vaporises and resects the prostate using a surgical technique similar to TURP. The small amount of study data currently available suggests that ThuVARP may have certain advantages over TURP, including reduced blood loss and shorter hospital stay, earlier return to normal activities, and shorter duration of catheterisation. DESIGN: A multicentre, pragmatic, randomised, controlled, parallel-group trial of ThuVARP versus standard TURP in men with BPO. Four hundred and ten men suitable for prostate surgery were randomised to receive either ThuVARP or TURP at four university teaching hospitals, and three district general hospitals. The key aim of the trial is to determine whether ThuVARP is equivalent to TURP judged on both the patient-reported International Prostate Symptom Score (IPSS) and the maximum urine flow rate (Qmax) at 12 months post-surgery. DISCUSSION: The general population has an increased life expectancy. As men get older their prostates enlarge, potentially causing BPO, which often requires surgery. Therefore, as the population ages, more prostate operations are needed to relieve obstruction. There is hence sustained interest in the condition and increasing need to find safer techniques than TURP. Various laser techniques have become available but none are widely used in the NHS because of lengthy training required for surgeons or inferior performance on clinical outcomes. Promising initial evidence from one RCT shows that ThuVARP has equivalent clinical effectiveness when compared to TURP, as well as other potential advantages. As ThuVARP uses a technique similar to that used in TURP, the learning curve is short, potentially making it also very quickly generalisable. This randomised study is designed to provide the high-quality evidence, in an NHS setting, with a range of patient-reported, clinical and cost-effectiveness outcomes, which will underpin and inform future NICE guidance. TRIAL REGISTRATION: ISRCTN registry, ISRCTN00788389 . Registered on 20 September 2013.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Worthington J, Taylor H, Abrams P, et al. A randomised controlled trial to determine the clinical and cost effectiveness of thulium laser transurethral vaporesection of the prostate (ThuVARP) versus transurethral resection of the prostate (TURP) in the National Health Service (NHS) - the UNBLOCS trial: a study protocol for a randomised controlled trial. Trials. 2017. PMID: 28412960. doi:10.1186/s13063-017-1916-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。